Sarepta Therapeutics (SRPT): STAT News Article Adds Uncertainty to SRP-9001's BLA - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)."We believe this ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
